Detalhe da pesquisa
1.
Clinical and humoral responses after SARS-CoV-2 breakthrough infections in patients with immunosuppressants.
J Allergy Clin Immunol;
2024 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38763170
2.
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Allergy;
2024 Mar 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38439527
3.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
J Neurol Neurosurg Psychiatry;
2024 Mar 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38548324
4.
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
Ther Drug Monit;
46(3): 410-414, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38287880
5.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun;
135: 102984, 2023 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36621174
6.
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
BMC Infect Dis;
23(1): 332, 2023 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37198536
7.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
BMC Med;
20(1): 100, 2022 03 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35236350
8.
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
Ann Rheum Dis;
81(6): 768-779, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35110331
9.
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis;
81(12): 1757-1766, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36357161
10.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Ann Rheum Dis;
82(6): 883-885, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36720583
11.
Time to talk to adults with rheumatic diseases about herpes zoster vaccination.
Lancet Rheumatol;
6(4): e247-e251, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38373432
12.
Work participation and the COVID-19 pandemic: an observational study in people with inflammatory rheumatic diseases and population controls.
Rheumatol Adv Pract;
8(2): rkae026, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38566834
13.
Patient-perspective and feasibility of home finger-prick testing to complement and facilitate large-scale research in rheumatology.
RMD Open;
10(2)2024 Apr 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38642927
14.
Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection.
Front Immunol;
15: 1314507, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38487524
15.
Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated.
RMD Open;
9(4)2023 12 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38053460
16.
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands.
Lancet Rheumatol;
5(7): e375-e385, 2023 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37398978
17.
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Neurol Neuroimmunol Neuroinflamm;
9(4)2022 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35523569
18.
Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.
Elife;
112022 07 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35838348
19.
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.
RMD Open;
8(1)2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35383121
20.
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Lancet Rheumatol;
4(6): e417-e429, 2022 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35527808